# ImmuCell (ICCC) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ICCC
## Company Profile
- Ticker: ICCC
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 10.75 USD
- Market cap: 88568162.21 USD
- Last updated: 2026-08-05
## Business Overview
### Animal Health Biologics Company
ImmuCell develops biologic products intended to improve calf health and productivity. The company primarily serves dairy and livestock markets, with an emphasis on preventing early-life diseases such as neonatal calf diarrhea.
### First Defense Franchise
The First Defense product line orally delivers antibodies derived from colostrum to provide immediate immune protection against major viral and bacterial causes of calf scours. Dual-Force and Tri-Shield are the franchise’s key growth products.
### Commercial Execution
Growth depends on product availability, U.S. market demand, expansion of the commercial team, and distributor inventory cycles. The release did not identify a specific future clinical or regulatory milestone.
## Why The Stock Is Moving

The latest monitored company update is “ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- ImmuCell’s catalysts are animal-health product demand, manufacturing execution, and steady recurring revenue in veterinary biologics. The company moves on operating consistency rather than binary headlines.

## Recent News
- 2026-08-06 20:05 EST — [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026](https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-june-30-2-53516e1a) — Source: ImmuCell
- 2026-07-09 20:05 EST — [ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results](https://biopharmsignal.com/news/ICCC/immucell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a-21-increas-9613a4a9) — Source: ImmuCell
- 2026-05-14 20:05 EST — [ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ICCC/immucell-announces-unaudited-financial-results-for-the-quarter-ended-march-31-20-d73ca2ba) — Source: ImmuCell
- 2026-05-07 20:05 EST — [ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ICCC/immucell-to-announce-unaudited-financial-results-for-the-quarter-ended-march-31--4b91433e) — Source: ImmuCell
- 2026-04-13 20:38 EST — [ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors](https://biopharmsignal.com/news/ICCC/immucell-bolsters-its-innovation-strategy-with-appointments-of-dr-gilles-guillem-0dff31ee) — Source: ImmuCell